AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06745635 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Usual Care
Description: Usual care for immunizations.
Study NCT06745635 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Multifaceted intervention
Description: The multifaceted quality improvement intervention includes: video-based training on vaccine management in SUS, an optimized Cold Chain Manual schema, technical documents on proper vaccine handling and immunization schedules, and checklists for managing post-vaccination errors and corrective procedures. Videos will focus on six key points (right person, vaccine, dose, time, route, and documentation), with each lasting about 2 minutes and accessible on-demand. The Cold Chain schema will cover storage, monitoring, transport, conservation, and handling, with checklists for each category. Standardized technical documents will align with video themes, ensuring protocol adherence. An error identification and management schema will address issues like improper vaccine administration, cold chain violations, and incorrect dosages. This schema will be reviewed by staff and made available in health units.
Study NCT06744634 — intervention group
Intervention type: OTHER
Intervention: Romania group
Description: The questionnaire which was prepared by researchers will be performed by older adults from Romania. The sociodemographic characteristics are recorded to part A section of questionnaire. The pain assessment section is part B and evaluate pain localization, intensity, type, factors affecting the pain, coping and management strategies of pain. Health related outcomes will be evaluated with CDC (Center of Disease Control and Prevention) Health related Quality of Life-4 Questionnaire
Study NCT06744634 — intervention group
Intervention type: OTHER
Intervention: Turkey Group
Description: The questionnaire which was prepared by researchers will be performed by older adults from Turkey The sociodemographic characteristics are recorded to part A section of questionnaire. The pain assessment section is part B and evaluate pain localization, intensity, type, factors affecting the pain, coping and management strategies of pain. Health related outcomes will be evaluated with CDC (Center of Disease Control and Prevention) Health related Quality of Life-4 Questionnaire
Study NCT06744634 — intervention group
Intervention type: OTHER
Intervention: Croatia Group
Description: The questionnaire which was prepared by researchers will be performed by older adults from Croatia. The sociodemographic characteristics are recorded to part A section of questionnaire. The pain assessment section is part B and evaluate pain localization, intensity, type, factors affecting the pain, coping and management strategies of pain. Health related outcomes will be evaluated with CDC (Center of Disease Control and Prevention) Health related Quality of Life-4 Questionnaire
Study NCT06745895 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MATCHES
Description: Participants will be asked to complete a survey with specific topics including Hepatitis C (HCV) and Colorectal (CRC) knowledge and health beliefs, screening intentions and demographic characteristics.~Participants will be provided with education intervention materials (for example, a booklet) either in-person or via mail, access to free stool-based CRC screening, and access to free HCV screening.~Approximately 1-2 weeks after receiving the education materials, participants will be asked to complete a post-intervention survey about the same specific topics (for example, HCV and CRC knowledge, HCV and CRC health beliefs, HCV and CRC screening intentions, healthcare experiences, perceptions of the educational materials) over the phone with a trained study staff.~Participants with a positive HCV screening and/or CRC screening result will be navigated to follow-up care as needed.
Study NCT06745765 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual reality headset
Description: Patients will use virtual reality before the procedure in addition to usual preoperative care.
Study NCT06744946 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: thoracoscope
Description: bleomycin- tranxemic acid mixture pleurodesis versus thoracoscopic talc poudrage
Study NCT06744348 — intervention group
Intervention type: PROCEDURE
Intervention: ENTİRE PAPİLLA PRESERVATİON
Description: The EPP technique is a tunnel-like approach of the defect-associated inter-dental papilla. Surgical loupes (3.3× magnification) with LED light illumination were used to increase visibility of the surgical site. Following a buccal intra-crevicular incision, a bevelled vertical releasing incision was performed in the buccal gingiva of the neighbouring inter-dental space and extended just beyond the mucogingival line to provide appropriate mechanical access to the intrabony defect.
Study NCT06745622 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HSK39297 tablets
Description: HSK39297 tablets until the end of treatment
Study NCT06744478 — intervention group
Intervention type: DEVICE
Intervention: Misight 1 Day Contact Lens
Description: Misight 1 Day Contact Lens wearing for myopia control
Study NCT06745544 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rhythm- and Multitask-Based Activity (RYMA) and Activities of Daily Living (ADL)
Description: The Rhythm- and Multitask-Based Activity (RYMA) program is a unique cognitive-motor exercise intervention designed for older adults with diabetes. It incorporates rhythm-based multitasking exercises, performed to improvised piano music, combined with Activities of Daily Living (ADL)-focused exercises. The intervention targets physical (strength, balance, and coordination) and cognitive (executive function, reaction time) components to reduce fall risk, improve bone health, and optimize cardiovascular outcomes. Delivered over 26 weeks, the program emphasizes social interaction to enhance adherence and long-term engagement.
Study NCT06734923 — intervention group
Intervention type: OTHER
Intervention: Questionnaire (28 questions)
Description: demographic data, information-seeking behavior, platform use and online consultation habits, trust and impact, and interest in additional resources
Study NCT06744751 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fecal Microbiota Transplantation
Description: Patients take the capsules once daily, with a dose of 4 capsules per day, for a total of 12 days (48 capsules in total). Capsule size is selected based on age: patients under 16 use size 3 capsules, while those 16 and older use size 0 capsules. Both the FMT and placebo capsules are identical in appearance, size, color, form, weight, and taste, with the placebo containing starch as the main ingredient.
Study NCT06744751 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Manufactured by the same company, the placebo capsules contain starch as the main ingredient and are identical in appearance, size, color, dosage form, weight, and taste to the FMT capsules. They are administered once daily, 4 capsules per dose, for 12 days.
Study NCT06744244 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Olfactory Testing
Description: Olfactory Test: Odor stimuli will be administered using a custom-designed olfactometer, developed by engineers specifically for this study. The olfactometer will release different odorants (maternal breast milk, vanilla essential oil, rose essential oil, and water as a control) in a controlled way. Each odor will be presented between 6 and 72 hours of life for 10 seconds (On), followed by a 50-second pause (Off) for a total of 15 cycles (On-Off). A new odor will be presented 5 minutes after the previous one. The first olfactory test will be conducted during the Video-EEG recording, and the second one will take place during the fMRI acquisition.
Study NCT06744244 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Heart rate (HR), Heart Rate Variability (HRV), Respiratory Rate (RR), peripheral oxygen saturation (SpO2)
Description: Simultaneously with the presentation of odors, heart rate (HR), heart rate variability (HRV), respiratory rate (RR), and peripheral oxygen saturation (SpO2) will be monitored and recorded. The onset of the odor will be recorded using a manual timer.
Study NCT06744244 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Video-EEG
Description: The infant's Video-EEG, as per guidelines following perinatal asphyxia, will be recorded for approximately 2 hours, including the period preceding odor administration (baseline).
Study NCT06744244 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: fMRI
Description: Newborns will undergo an fMRI, as part of routine clinical practice, to identify any brain injury, its extent, and the structures involved. The use of a custom-built fMRI compatible olfactometer will facilitate these studies.
Study NCT06744244 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Neurodevelopment assessment
Description: Between 12 and 18 months, the infants will undergo neurodevelopmental follow-up, during which the Bayley III assessment will be administered to evaluate any potential neurocognitive deficits.
Study NCT06745193 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chidamide+Camrelizumab+Apatinib
Description: chidamide+Camrelizumab+Apatinib
Study NCT05402046 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mobile phone application ProRodinki
Description: Patient were underwent photography using mobile phone and tested application ProRodinkijust before preplanned excisional or incisional biopsy.~Application AI result than will be compared with pathology report by independent investigator
Study NCT06745193 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Irinotecan or Docetaxel or Paclitaxel
Description: Irinotecan Docetaxel Paclitaxel
Study NCT06744361 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: esketamine hydrochloride
Description: Prehospital intravenous or intraosseous bolus administration at a minimum of 0.5 mg/kg of esketamine
Study NCT06744361 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propofol
Description: Prehospital intravenous or intraosseous bolus administration at a minimum dose of 0.25 mg/kg propofol
Study NCT06678594 — intervention group
Intervention type: PROCEDURE
Intervention: Calcium modification
Description: Patients will undergo one or more of the following procedures, subject to the algorithm:~Angioplasty Balloon Cutting Balloon Rotational Atherectomy Intravascular Lithotripsy
Study NCT06677697 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0,5%
Description: Group B 30 patients recive 0.5% ropivacine
Study NCT06677762 — intervention group
Intervention type: PROCEDURE
Intervention: Irreversible electroporation
Description: Irreversible electroporation ablation is an interventional ablation method, while anti-PD(L)1 is an immunotherapy.
Study NCT06678386 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 50% sugar reduction
Description: Participants were advised by a dietitian to reduce their daily caloric intake from sugars by 50% for 12 weeks.
Study NCT06152848 — intervention group
Intervention type: OTHER
Intervention: Data and samples collection
Description: Collection of clinical, anamnestic and lifestyle data; collection of faecal, blood and saliva samples
Study NCT06744894 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor combined with Ixazomib and Lenalidomide as Maintenance Therapy
Description: Patients were treated by Selinexor (40mg po qw d1-28) combined with Ixazomib (4mg po on days 1, 8, and 15 in 28-day cycles) and Lenalidomide(10mg po qd d1-21) as Maintenance Therapy.
Study NCT06744569 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CU-10101
Description: 0.3%CU-10101 ；1%CU-10101 ；2%CU-10101； Placebo
Study NCT06743724 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: repeated transcranial magnetic stimulation treatment
Description: Patients with low score of Maternal Care Rating Scale received repetitive transcranial magnetic stimulation at 1 Hz/s for 20 minutes for 2 week.
Study NCT05436418 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Matched HCT: 100 mg/m\^2 IV on day -2 over 30 minutes. Haplo HCT:~100 mg/m\^2 IV on day -6 over approximately 20-30 minutes.
Study NCT05436418 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Sirolimus: Loading dose of 6 mg orally given on day +5 (calculated based on actual body weight, max initial dose 6 mg)\^d, then maintenance dose starting at 2 mg orally daily on day +6 with dose adjustments to maintain a trough of 5-12 ng/ml, continued through day +80 with no taper. Doses should be modified as appropriate for drug interactions and may be modified based on institutional practice.
Study NCT05350436 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Balance Conditions
Description: Balance Conditions: (\~ 5 minutes in total)~* Balance Condition 1 (Feet 20cm apart)~* Balance Condition 2 (Feet together)~* Balance Condition 3 (Tandem stance)~Initial measurements of balance conditions serve two purposes: it generates a postural control baseline for us without the attribution of singing conditions, furthermore it allows us to separately measure long-term singing experience's effect on postural control, by assessing tasks differing in difficulty level. Balance conditions will be randomised to prevent a learning effect.
Study NCT05350436 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Singing
Description: Singing Conditions: (\~ 15 minutes)~* Warmup - including jaw and breathing exercises~* Singing Condition 1 (Spoken Happy Birthday - Traditional Tempo)~* Singing Condition 2 (Sung Happy Birthday - Traditional Tempo~* Singing Condition 3 (Spoken Happy Birthday - Fast Tempo)~* Singing Condition 4 (Sung Happy Birthday - Fast Tempo)~* Singing Condition 5 (Spoken Happy Birthday - Slow Tempo)~* Singing Condition 6 (Sung Happy Birthday - Slow Tempo)~Link to singing instructional video:~https://www.dropbox.com/s/tro58i6vx6i6w3a/Singing%20Balance%20Exercise%20Video.mp4?dl=0~Time stamps for the video:~* Warmup (including jaw exercises and breathing exercises) - beginning at 2:55 until 6:06~* Happy Birthday protocol - beginning at 15:26 until 20:21
Study NCT06174480 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cryostimulation
Description: Cryostimulation (-50°C, forced ventilation for 3 minutes) during 20 sessions over 2 weeks.
Study NCT05194007 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Frondanol
Description: Frondanol capsule (1000 mg) will be administered orally (Twice daily) in the double blind settings
Study NCT05194007 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (corn starch) capsule will be administered orally (Twice daily) in the double blind settings
Study NCT05717075 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Parents Round
Description: The intervention carried out in this study is called Family Round. The Family Round is an additional medical round, aiming to involve parents in the discussion. The basic attitude of the healthcare staff is to make decisions collaboratively with parents or other family members based on the parents' observations of their infant and parents' opinions. As our daily medical round is carried out in the morning between 8 and 10 a.m. and we offer no accommodation for parents in the NICU, the Family Round will be carried out separately in the afternoon. One neonatologist who is in charge of the infant or taking care of the infant on that day will be a facilitator and proceed with the Parent Round according to the protocol. Other healthcare staff are also encouraged to participate, although the number of participants is limited.
Study NCT05436418 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total Body Irradiation (TBI)
Description: Haplo HCT only: A dose of 200 cGy will be administered on day -1.
Study NCT05420467 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: 600 mg/m2, d1, q3w × 4 cycles followed by docetaxel
Study NCT05420467 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: 100 mg/m2, d1, q3w × 4 cycles
Study NCT05420467 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin
Description: 90 mg/m2,d1, q2w × 4 cycles followed by nab-paclitaxel
Study NCT05420467 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 600 mg/m2, d1, q2w × 4 cycles followed by nab-paclitaxel
Study NCT05436418 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: based on dose level being tested (50, 35, 25, or 15 mg/kg) IV once daily over 2 hours on days +3 and +4. Cyclophosphamide will be dosed according to ideal body weight. Cyclophosphamide infusion on days +3 should be started between 70-74 hours after the start of the PBSC infusion. Cyclophosphamide infusion on day +4 should be started between 94-98 hours after the start of the bone marrow infusion.
Study NCT05420467 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab paclitaxel
Description: 125 mg/m2, d1,8,15, q3w× 4 cycles
Study NCT05196737 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dry Needling
Description: Dry needling is a procedure in which a thin, stainless steel needle is inserted into the skin to produce a muscle twitch response. It is intended to release a knot in a muscle and relieve pain.
Study NCT06391372 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: estriol cream
Description: 1 g intravaginal estriol via applicator twice a week before going to bed for 4 weeks
Study NCT05762653 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Endoscopic ultrasound
Description: Evaluation of pancreatic fibrosis by endoscopic ultrasound and elastography. Evaluation of exocrine pancreatic function by fecal elastase-test and nutritional evaluation.
Study NCT06404762 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: tSCTG+ CAF
Description: In the tSCTG group, at the distal end of a second maxillary molar, an incision will be made using a double-bladed scalpel (SKU 10-130-05D; Hu-Friedy, Chicago, IL, USA) bucco-palatally, forming a 1,5 mm thick parallel line. Secondary incisions will be made to separate the graft using a 15c blade on the buccal and palatal sides. Later, the graft will be de-epithelialized extra-orally using a blade
Study NCT06404762 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: pSCTG+ CAF
Description: In pSCTG group; the graft will be harvested through a single-incision approach at the lateral palatal mucosa
Study NCT06585540 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amisulpride IV Prevention
Description: Patients in this arm will receive Amisulpride 5mg IV as a preventative dose after the induction of anesthesia
Study NCT06585540 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amisulpride IV Treatment
Description: Patients in this arm will receive Amisulpride 10mg IV for first-line treatment of Post-Operative Nausea and Vomiting in the post-anesthesia care unit.
Study NCT06585540 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Preventative
Description: Patients in this arm will receive placebo (Normal Saline) while under general anesthesia
Study NCT06585540 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Treatment
Description: Patients in this Arm will receive placebo as first line treatment of Post-Operative Nausea and Vomiting in the Post Anesthesia Care Unit
Study NCT05420467 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: 600 mg/m2, d1, q3w × 6 cycles
Study NCT05420467 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 600 mg/m2, d1, q3w × 6 cycles
Study NCT05436418 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofeti
Description: 15 mg/kg orally or IV three times daily (max 1000 mg/dose) starting on day +5, continued through day +35. Dosing will be according to actual body weight.
Study NCT05436418 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Matched HCT: 25 mg/m\^2/day infused IV over 60 minutes from day -7 to day -3. Haplo HCT: 40 mg/m\^2/day infused IV over approximately 30-60 minutes from day -5 to day -2
Study NCT06005636 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Test delirium state
Description: use scale to test whether ischemic stroke patients have post-stroke delirium
Study NCT05505786 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Normal stance width
Description: Normal self-selected stance width when performing squat exercises.
Study NCT05395572 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Kinesio® Tape
Description: In order to increase the activity of underactive muscles, the tape is applied from origin to insertion with a 15-25% tension. The Kinesio® Tape mechanical muscle correction will be performed with one Y-strip of Kinesio® Tape over the bilateral cervical multifidus and semispinalis cervicis muscles, while also including portions of other cervical extensor muscles (the semispinalis capitis, splenius cervicis, levator scapulae, upper trapezius, longus coli, and splenius capitis).
Study NCT05136742 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: aerobic exercise and diet program
Description: It is an interventional study in which 60 women estimated to enrol according to random allocation and assigned into two groups equal. The study group will receive aerobic exercises in addition to diet recommendations while the control group will receive diet recommendations. the aerobic exercises in form of treadmill training intensity of exercises high intensity, target heart rate (THR) will be60-70% of heart maximum (HR MAX)time of session 40 min initial 10 min warm up exercise on treadmill in low intensity and active phase20- 30 min intensity will increase until patient reach to THR then intensity decrease until session will be ended by cooling down phase for 10 min . The volunteers will perform exercises 3 times per week for 12 weeks .insulin resistance will be measured by HOMA -IR index and sex hormones (estridol ,testosterone. sex hormone binding globin ) pre and post intervention and use zung self-rating depression scale to assess depression
Study NCT05136742 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: diet program
Description: balanced restricted diet